Company intelligence / Profile preview
Kowa Pharmaceuticals
Nagoya, Aichi, Japankowapharma.com ↗
- Ownership
- Private
- Employees
- ~8000
- Development stage
- Commercial
01
Overview
Kowa has successfully commercialized several products—most notably LIVALO® (pitavastatin) for dyslipidemia—and maintains a robust pipeline targeting cardiometabolic, ophthalmologic, hepatic, and metabolic diseases. Its clinical-stage assets include both monotherapies and combination drugs with ongoing trials in the US, Europe, Japan, and Asia. Recent filings cover new indications for existing drugs as well as novel combinations.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersOphthalmology
- Modalities
- Small moleculesCombination therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kowa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kowa Pharmaceuticals.